Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma by R Dummer, M Guggenheim, AW Arnold, R Braun

Get full text

Health‐related quality of life in survivors of advanced melanoma treated with anti‐PD1‐based immune checkpoint inhibitors by E. L. Looman, P. F. Cheng, J. Lai‐Kwon, L. Morgan, M. Wakkee, R. Dummer, F. Dimitriou

Get full text

Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect by J. Boegeholz, C. S. Brueggen, C. Pauli, F. Dimitriou, E. Haralambieva, R. Dummer, M. G. Manz, C. C. Widmer

Get full text

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors by H. S. Gabryś, L. Basler, S. Burgermeister, S. Hogan, M. Ahmadsei, M. Pavic, M. Bogowicz, D. Vuong, S. Tanadini-Lang, R. Förster, K. Kudura, M. Huellner, R. Dummer, M. P. Levesque, M. Guckenberger

Get full text

Predictors of responses to immune checkpoint blockade in advanced melanoma by N. Jacquelot, M. P. Roberti, D. P. Enot, S. Rusakiewicz, N. Ternès, S. Jegou, D. M. Woods, A. L. Sodré, M. Hansen, Y. Meirow, M. Sade-Feldman, A. Burra, S. S. Kwek, C. Flament, M. Messaoudene, C. P. M. Duong, L. Chen, B. S. Kwon, A. C. Anderson, V. K. Kuchroo, B. Weide, F. Aubin, C. Borg, S. Dalle, O. Beatrix, M. Ayyoub, B. Balme, G. Tomasic, A. M. Di Giacomo, M. Maio, D. Schadendorf, I. Melero, B. Dréno, A. Khammari, R. Dummer, M. Levesque, Y. Koguchi, L. Fong, M. Lotem, M. Baniyash, H. Schmidt, I. M. Svane, G. Kroemer, A. Marabelle, S. Michiels, A. Cavalcanti, M. J. Smyth, J. S. Weber, A. M. Eggermont, L. Zitvogel

Get full text